Brief: Celularity Inc - Clinical Data On Cynk-001 In Adult Patients With Relapsed Refractory And Measurable Residual Disease-Positive Acute Myeloid Leukemia
27/04/2023 23:04
April 27 (Reuters) - Celularity Inc CELU.O :
* CELULARITY INC - CLINICAL DATA ON CYNK-001 IN ADULT
PATIENTS
WITH RELAPSED REFRACTORY AND MEASURABLE RESIDUAL
DISEASE-POSITIVE ACUTE MYELOID LEUKEMIA
* CELULARITY:IN PATIENTS WITH RELAPSED REFRACTORY ACUTE
MYELOID
LEUKEMIA TREATED WITH 4-DOSE REGIMEN 2 OF 4 PATIENTS ACHIEVED
OBJECTIVE RESPONSE AT DAY-28
Further company coverage: CELU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celularity
See all newsU.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform